NCT05865041View on ClinicalTrials.gov

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

September 12, 2024

Study Completion Date

October 31, 2024

Conditions
Alopecia Areata
Interventions
DRUG

Farudodstat

Farudodstat tablets administered orally

DRUG

Placebo

Placebo tablets administered orally

Trial Locations (19)

20037

RECRUITING

1 Site, Washington D.C.

33134

RECRUITING

1 Site, Coral Gables

35205

RECRUITING

1 Site, Birmingham

37215

RECRUITING

1 Site, Nashville

40241

RECRUITING

1 Site, Louisville

43215

RECRUITING

1 Site, Columbus

44195

RECRUITING

1 Site, Cleveland

46250

RECRUITING

1 Site, Indianapolis

55112

RECRUITING

1 Site, New Brighton

55455

RECRUITING

1 Site, Minneapolis

64506

RECRUITING

1 Site, Saint Joseph

68114

RECRUITING

1 Site, Omaha

77598

RECRUITING

1 Site, Webster

78218

RECRUITING

2 Sites, San Antonio

78660

RECRUITING

1 Site, Pflugerville

92701

RECRUITING

1 Site, Santa Ana

92708

RECRUITING

1 Site, Fountain Valley

06519

RECRUITING

1 Site, New Haven

02135

RECRUITING

1 Site, Brighton

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER